nodes	percent_of_prediction	percent_of_DWPC	metapath
Dobutamine—CA2—Imatinib—hematologic cancer	0.217	0.524	CbGbCtD
Dobutamine—CA2—Nilotinib—hematologic cancer	0.197	0.476	CbGbCtD
Dobutamine—CA5B—hematopoietic system—hematologic cancer	0.00364	0.0924	CbGeAlD
Dobutamine—COMT—hematopoietic system—hematologic cancer	0.00336	0.0851	CbGeAlD
Dobutamine—CA5B—gonad—hematologic cancer	0.00277	0.0702	CbGeAlD
Dobutamine—Masoprocol—ALOX5—hematologic cancer	0.00262	0.767	CrCbGaD
Dobutamine—COMT—gonad—hematologic cancer	0.00255	0.0647	CbGeAlD
Dobutamine—CA5B—blood—hematologic cancer	0.00241	0.0612	CbGeAlD
Dobutamine—COMT—blood—hematologic cancer	0.00222	0.0564	CbGeAlD
Dobutamine—COMT—bone marrow—hematologic cancer	0.00215	0.0546	CbGeAlD
Dobutamine—CA5B—lung—hematologic cancer	0.00212	0.0537	CbGeAlD
Dobutamine—CA2—hematopoietic system—hematologic cancer	0.00209	0.0529	CbGeAlD
Dobutamine—CA5B—testis—hematologic cancer	0.002	0.0506	CbGeAlD
Dobutamine—COMT—lung—hematologic cancer	0.00195	0.0494	CbGeAlD
Dobutamine—COMT—testis—hematologic cancer	0.00184	0.0466	CbGeAlD
Dobutamine—ADRB1—lung—hematologic cancer	0.00165	0.0419	CbGeAlD
Dobutamine—CA5B—lymph node—hematologic cancer	0.00145	0.0367	CbGeAlD
Dobutamine—CA2—blood—hematologic cancer	0.00138	0.035	CbGeAlD
Dobutamine—CA2—bone marrow—hematologic cancer	0.00134	0.0339	CbGeAlD
Dobutamine—COMT—lymph node—hematologic cancer	0.00133	0.0338	CbGeAlD
Dobutamine—CA2—lung—hematologic cancer	0.00121	0.0307	CbGeAlD
Dobutamine—CA2—testis—hematologic cancer	0.00114	0.029	CbGeAlD
Dobutamine—Hypotension—Dasatinib—hematologic cancer	0.000832	0.00207	CcSEcCtD
Dobutamine—CA2—lymph node—hematologic cancer	0.000829	0.021	CbGeAlD
Dobutamine—Thrombocytopenia—Chlorambucil—hematologic cancer	0.000823	0.00205	CcSEcCtD
Dobutamine—Nausea—Mechlorethamine—hematologic cancer	0.000814	0.00202	CcSEcCtD
Dobutamine—Thrombocytopenia—Nilotinib—hematologic cancer	0.000805	0.002	CcSEcCtD
Dobutamine—Tachycardia—Nilotinib—hematologic cancer	0.000802	0.002	CcSEcCtD
Dobutamine—Thrombocytopenia—Imatinib—hematologic cancer	0.0008	0.00199	CcSEcCtD
Dobutamine—Pruritus—Methoxsalen—hematologic cancer	0.000798	0.00199	CcSEcCtD
Dobutamine—Tachycardia—Imatinib—hematologic cancer	0.000798	0.00198	CcSEcCtD
Dobutamine—Dopamine—SLC22A1—hematologic cancer	0.000796	0.233	CrCbGaD
Dobutamine—Dyspnoea—Dasatinib—hematologic cancer	0.000793	0.00197	CcSEcCtD
Dobutamine—Dyspnoea—Bexarotene—hematologic cancer	0.000793	0.00197	CcSEcCtD
Dobutamine—Dyspnoea—Fludarabine—hematologic cancer	0.000791	0.00197	CcSEcCtD
Dobutamine—Thrombocytopenia—Cladribine—hematologic cancer	0.000787	0.00196	CcSEcCtD
Dobutamine—Tachycardia—Cladribine—hematologic cancer	0.000784	0.00195	CcSEcCtD
Dobutamine—Palpitations—Lenalidomide—hematologic cancer	0.000772	0.00192	CcSEcCtD
Dobutamine—Hypotension—Nilotinib—hematologic cancer	0.000768	0.00191	CcSEcCtD
Dobutamine—Pruritus—Daunorubicin—hematologic cancer	0.000765	0.0019	CcSEcCtD
Dobutamine—Pruritus—Clofarabine—hematologic cancer	0.000765	0.0019	CcSEcCtD
Dobutamine—Chest pain—Melphalan—hematologic cancer	0.000764	0.0019	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Epirubicin—hematologic cancer	0.000764	0.0019	CcSEcCtD
Dobutamine—Hypotension—Imatinib—hematologic cancer	0.000764	0.0019	CcSEcCtD
Dobutamine—Pruritus—Pentostatin—hematologic cancer	0.000762	0.00189	CcSEcCtD
Dobutamine—Pruritus—Anagrelide—hematologic cancer	0.000762	0.00189	CcSEcCtD
Dobutamine—Thrombocytopenia—Vinblastine—hematologic cancer	0.000754	0.00188	CcSEcCtD
Dobutamine—Hypotension—Cladribine—hematologic cancer	0.000751	0.00187	CcSEcCtD
Dobutamine—Chest pain—Lenalidomide—hematologic cancer	0.000743	0.00185	CcSEcCtD
Dobutamine—Dyspnoea—Nilotinib—hematologic cancer	0.000733	0.00182	CcSEcCtD
Dobutamine—Dyspnoea—Imatinib—hematologic cancer	0.000729	0.00181	CcSEcCtD
Dobutamine—Headache—Nelarabine—hematologic cancer	0.000724	0.0018	CcSEcCtD
Dobutamine—Thrombocytopenia—Melphalan—hematologic cancer	0.000718	0.00178	CcSEcCtD
Dobutamine—Dyspnoea—Cladribine—hematologic cancer	0.000716	0.00178	CcSEcCtD
Dobutamine—Tachycardia—Melphalan—hematologic cancer	0.000715	0.00178	CcSEcCtD
Dobutamine—Pruritus—Teniposide—hematologic cancer	0.000714	0.00178	CcSEcCtD
Dobutamine—Palpitations—Bortezomib—hematologic cancer	0.00071	0.00177	CcSEcCtD
Dobutamine—Headache—Methoxsalen—hematologic cancer	0.000707	0.00176	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Doxorubicin—hematologic cancer	0.000707	0.00176	CcSEcCtD
Dobutamine—Skin exfoliation—Methotrexate—hematologic cancer	0.000704	0.00175	CcSEcCtD
Dobutamine—Thrombocytopenia—Lenalidomide—hematologic cancer	0.000698	0.00173	CcSEcCtD
Dobutamine—Tachycardia—Lenalidomide—hematologic cancer	0.000695	0.00173	CcSEcCtD
Dobutamine—Palpitations—Vinorelbine—hematologic cancer	0.000693	0.00172	CcSEcCtD
Dobutamine—Thrombocytopenia—Hydroxyurea—hematologic cancer	0.000688	0.00171	CcSEcCtD
Dobutamine—Nausea—Nelarabine—hematologic cancer	0.000686	0.00171	CcSEcCtD
Dobutamine—Hypotension—Melphalan—hematologic cancer	0.000685	0.0017	CcSEcCtD
Dobutamine—Chest pain—Bortezomib—hematologic cancer	0.000684	0.0017	CcSEcCtD
Dobutamine—Chest pain—Bleomycin—hematologic cancer	0.000679	0.00169	CcSEcCtD
Dobutamine—Headache—Daunorubicin—hematologic cancer	0.000677	0.00168	CcSEcCtD
Dobutamine—Headache—Clofarabine—hematologic cancer	0.000677	0.00168	CcSEcCtD
Dobutamine—Headache—Anagrelide—hematologic cancer	0.000674	0.00168	CcSEcCtD
Dobutamine—Headache—Pentostatin—hematologic cancer	0.000674	0.00168	CcSEcCtD
Dobutamine—Nausea—Methoxsalen—hematologic cancer	0.00067	0.00167	CcSEcCtD
Dobutamine—Hypokalaemia—Dexamethasone—hematologic cancer	0.000669	0.00166	CcSEcCtD
Dobutamine—Hypokalaemia—Betamethasone—hematologic cancer	0.000669	0.00166	CcSEcCtD
Dobutamine—Chest pain—Vinorelbine—hematologic cancer	0.000668	0.00166	CcSEcCtD
Dobutamine—Hypotension—Lenalidomide—hematologic cancer	0.000666	0.00166	CcSEcCtD
Dobutamine—Pruritus—Busulfan—hematologic cancer	0.000662	0.00165	CcSEcCtD
Dobutamine—Skin exfoliation—Epirubicin—hematologic cancer	0.000659	0.00164	CcSEcCtD
Dobutamine—Dyspnoea—Melphalan—hematologic cancer	0.000653	0.00162	CcSEcCtD
Dobutamine—Nausea—Mercaptopurine—hematologic cancer	0.000651	0.00162	CcSEcCtD
Dobutamine—Headache—Idarubicin—hematologic cancer	0.00065	0.00162	CcSEcCtD
Dobutamine—Pruritus—Procarbazine—hematologic cancer	0.000642	0.0016	CcSEcCtD
Dobutamine—Nausea—Daunorubicin—hematologic cancer	0.000642	0.0016	CcSEcCtD
Dobutamine—Nausea—Clofarabine—hematologic cancer	0.000642	0.0016	CcSEcCtD
Dobutamine—Thrombocytopenia—Bortezomib—hematologic cancer	0.000642	0.0016	CcSEcCtD
Dobutamine—Palpitations—Thalidomide—hematologic cancer	0.00064	0.00159	CcSEcCtD
Dobutamine—Tachycardia—Bortezomib—hematologic cancer	0.00064	0.00159	CcSEcCtD
Dobutamine—Nausea—Pentostatin—hematologic cancer	0.000639	0.00159	CcSEcCtD
Dobutamine—Nausea—Anagrelide—hematologic cancer	0.000639	0.00159	CcSEcCtD
Dobutamine—Thrombocytopenia—Bleomycin—hematologic cancer	0.000637	0.00158	CcSEcCtD
Dobutamine—Dyspnoea—Lenalidomide—hematologic cancer	0.000635	0.00158	CcSEcCtD
Dobutamine—Headache—Teniposide—hematologic cancer	0.000633	0.00157	CcSEcCtD
Dobutamine—Pruritus—Dasatinib—hematologic cancer	0.00063	0.00157	CcSEcCtD
Dobutamine—Pruritus—Bexarotene—hematologic cancer	0.00063	0.00157	CcSEcCtD
Dobutamine—Pruritus—Fludarabine—hematologic cancer	0.000628	0.00156	CcSEcCtD
Dobutamine—Thrombocytopenia—Vinorelbine—hematologic cancer	0.000627	0.00156	CcSEcCtD
Dobutamine—Dyspnoea—Hydroxyurea—hematologic cancer	0.000626	0.00156	CcSEcCtD
Dobutamine—Tachycardia—Vinorelbine—hematologic cancer	0.000625	0.00155	CcSEcCtD
Dobutamine—Chest pain—Thalidomide—hematologic cancer	0.000617	0.00153	CcSEcCtD
Dobutamine—Nausea—Idarubicin—hematologic cancer	0.000617	0.00153	CcSEcCtD
Dobutamine—Hypotension—Bortezomib—hematologic cancer	0.000613	0.00152	CcSEcCtD
Dobutamine—Skin exfoliation—Doxorubicin—hematologic cancer	0.00061	0.00152	CcSEcCtD
Dobutamine—Palpitations—Alitretinoin—hematologic cancer	0.000609	0.00151	CcSEcCtD
Dobutamine—Hypotension—Bleomycin—hematologic cancer	0.000608	0.00151	CcSEcCtD
Dobutamine—Palpitations—Ifosfamide—hematologic cancer	0.000602	0.0015	CcSEcCtD
Dobutamine—Nausea—Teniposide—hematologic cancer	0.0006	0.00149	CcSEcCtD
Dobutamine—Thrombocytopenia—Thiotepa—hematologic cancer	0.000599	0.00149	CcSEcCtD
Dobutamine—Hypotension—Vinorelbine—hematologic cancer	0.000598	0.00149	CcSEcCtD
Dobutamine—Tachycardia—Thiotepa—hematologic cancer	0.000597	0.00148	CcSEcCtD
Dobutamine—Pruritus—Chlorambucil—hematologic cancer	0.000595	0.00148	CcSEcCtD
Dobutamine—Chest pain—Carmustine—hematologic cancer	0.000592	0.00147	CcSEcCtD
Dobutamine—Chest pain—Alitretinoin—hematologic cancer	0.000587	0.00146	CcSEcCtD
Dobutamine—Headache—Busulfan—hematologic cancer	0.000586	0.00146	CcSEcCtD
Dobutamine—Dyspnoea—Bortezomib—hematologic cancer	0.000585	0.00145	CcSEcCtD
Dobutamine—Hypokalaemia—Prednisone—hematologic cancer	0.000583	0.00145	CcSEcCtD
Dobutamine—Pruritus—Nilotinib—hematologic cancer	0.000582	0.00145	CcSEcCtD
Dobutamine—Phlebitis—Epirubicin—hematologic cancer	0.000581	0.00145	CcSEcCtD
Dobutamine—Dyspnoea—Bleomycin—hematologic cancer	0.00058	0.00144	CcSEcCtD
Dobutamine—Chest pain—Ifosfamide—hematologic cancer	0.00058	0.00144	CcSEcCtD
Dobutamine—Thrombocytopenia—Thalidomide—hematologic cancer	0.000579	0.00144	CcSEcCtD
Dobutamine—Pruritus—Imatinib—hematologic cancer	0.000578	0.00144	CcSEcCtD
Dobutamine—Tachycardia—Thalidomide—hematologic cancer	0.000577	0.00144	CcSEcCtD
Dobutamine—Dyspnoea—Vinorelbine—hematologic cancer	0.000571	0.00142	CcSEcCtD
Dobutamine—Headache—Procarbazine—hematologic cancer	0.000569	0.00141	CcSEcCtD
Dobutamine—Pruritus—Cladribine—hematologic cancer	0.000568	0.00141	CcSEcCtD
Dobutamine—Headache—Bexarotene—hematologic cancer	0.000557	0.00139	CcSEcCtD
Dobutamine—Headache—Dasatinib—hematologic cancer	0.000557	0.00139	CcSEcCtD
Dobutamine—Thrombocytopenia—Carmustine—hematologic cancer	0.000556	0.00138	CcSEcCtD
Dobutamine—Headache—Fludarabine—hematologic cancer	0.000556	0.00138	CcSEcCtD
Dobutamine—Nausea—Busulfan—hematologic cancer	0.000556	0.00138	CcSEcCtD
Dobutamine—Tachycardia—Carmustine—hematologic cancer	0.000554	0.00138	CcSEcCtD
Dobutamine—Hypotension—Thalidomide—hematologic cancer	0.000553	0.00137	CcSEcCtD
Dobutamine—Thrombocytopenia—Alitretinoin—hematologic cancer	0.000551	0.00137	CcSEcCtD
Dobutamine—Chest pain—Mitoxantrone—hematologic cancer	0.000551	0.00137	CcSEcCtD
Dobutamine—Tachycardia—Alitretinoin—hematologic cancer	0.000549	0.00137	CcSEcCtD
Dobutamine—Thrombocytopenia—Ifosfamide—hematologic cancer	0.000544	0.00135	CcSEcCtD
Dobutamine—Nausea—Procarbazine—hematologic cancer	0.000539	0.00134	CcSEcCtD
Dobutamine—Phlebitis—Doxorubicin—hematologic cancer	0.000538	0.00134	CcSEcCtD
Dobutamine—Chest pain—Gemcitabine—hematologic cancer	0.000537	0.00133	CcSEcCtD
Dobutamine—Thrombocytopenia—Vincristine—hematologic cancer	0.000531	0.00132	CcSEcCtD
Dobutamine—Hypotension—Carmustine—hematologic cancer	0.000531	0.00132	CcSEcCtD
Dobutamine—Nausea—Dasatinib—hematologic cancer	0.000529	0.00131	CcSEcCtD
Dobutamine—Nausea—Bexarotene—hematologic cancer	0.000529	0.00131	CcSEcCtD
Dobutamine—Dyspnoea—Thalidomide—hematologic cancer	0.000527	0.00131	CcSEcCtD
Dobutamine—Nausea—Fludarabine—hematologic cancer	0.000527	0.00131	CcSEcCtD
Dobutamine—Hypotension—Alitretinoin—hematologic cancer	0.000526	0.00131	CcSEcCtD
Dobutamine—Hypotension—Ifosfamide—hematologic cancer	0.00052	0.00129	CcSEcCtD
Dobutamine—Pruritus—Melphalan—hematologic cancer	0.000518	0.00129	CcSEcCtD
Dobutamine—Thrombocytopenia—Irinotecan—hematologic cancer	0.000517	0.00129	CcSEcCtD
Dobutamine—Thrombocytopenia—Mitoxantrone—hematologic cancer	0.000517	0.00129	CcSEcCtD
Dobutamine—Tachycardia—Mitoxantrone—hematologic cancer	0.000515	0.00128	CcSEcCtD
Dobutamine—Headache—Nilotinib—hematologic cancer	0.000515	0.00128	CcSEcCtD
Dobutamine—Headache—Imatinib—hematologic cancer	0.000512	0.00127	CcSEcCtD
Dobutamine—Hypotension—Vincristine—hematologic cancer	0.000507	0.00126	CcSEcCtD
Dobutamine—Dyspnoea—Carmustine—hematologic cancer	0.000506	0.00126	CcSEcCtD
Dobutamine—Pruritus—Lenalidomide—hematologic cancer	0.000504	0.00125	CcSEcCtD
Dobutamine—Thrombocytopenia—Gemcitabine—hematologic cancer	0.000504	0.00125	CcSEcCtD
Dobutamine—Headache—Cladribine—hematologic cancer	0.000503	0.00125	CcSEcCtD
Dobutamine—Dyspnoea—Alitretinoin—hematologic cancer	0.000502	0.00125	CcSEcCtD
Dobutamine—Nausea—Chlorambucil—hematologic cancer	0.000499	0.00124	CcSEcCtD
Dobutamine—Dyspnoea—Ifosfamide—hematologic cancer	0.000496	0.00123	CcSEcCtD
Dobutamine—Hypotension—Irinotecan—hematologic cancer	0.000493	0.00123	CcSEcCtD
Dobutamine—Hypotension—Mitoxantrone—hematologic cancer	0.000493	0.00123	CcSEcCtD
Dobutamine—Nausea—Nilotinib—hematologic cancer	0.000488	0.00121	CcSEcCtD
Dobutamine—Nausea—Imatinib—hematologic cancer	0.000486	0.00121	CcSEcCtD
Dobutamine—Headache—Vinblastine—hematologic cancer	0.000483	0.0012	CcSEcCtD
Dobutamine—Hypotension—Gemcitabine—hematologic cancer	0.000481	0.00119	CcSEcCtD
Dobutamine—Nausea—Cladribine—hematologic cancer	0.000477	0.00119	CcSEcCtD
Dobutamine—Dyspnoea—Mitoxantrone—hematologic cancer	0.000471	0.00117	CcSEcCtD
Dobutamine—Dyspnoea—Irinotecan—hematologic cancer	0.000471	0.00117	CcSEcCtD
Dobutamine—Thrombocytopenia—Cisplatin—hematologic cancer	0.000469	0.00117	CcSEcCtD
Dobutamine—Tachycardia—Cisplatin—hematologic cancer	0.000468	0.00116	CcSEcCtD
Dobutamine—Pruritus—Bortezomib—hematologic cancer	0.000464	0.00115	CcSEcCtD
Dobutamine—Pruritus—Bleomycin—hematologic cancer	0.00046	0.00114	CcSEcCtD
Dobutamine—Dyspnoea—Gemcitabine—hematologic cancer	0.000459	0.00114	CcSEcCtD
Dobutamine—Chest pain—Etoposide—hematologic cancer	0.000458	0.00114	CcSEcCtD
Dobutamine—Nausea—Vinblastine—hematologic cancer	0.000458	0.00114	CcSEcCtD
Dobutamine—Hypokalaemia—Epirubicin—hematologic cancer	0.000456	0.00113	CcSEcCtD
Dobutamine—Pruritus—Vinorelbine—hematologic cancer	0.000453	0.00113	CcSEcCtD
Dobutamine—Hypotension—Cisplatin—hematologic cancer	0.000448	0.00111	CcSEcCtD
Dobutamine—Headache—Lenalidomide—hematologic cancer	0.000446	0.00111	CcSEcCtD
Dobutamine—Headache—Hydroxyurea—hematologic cancer	0.00044	0.00109	CcSEcCtD
Dobutamine—Nausea—Melphalan—hematologic cancer	0.000435	0.00108	CcSEcCtD
Dobutamine—Pruritus—Thiotepa—hematologic cancer	0.000433	0.00108	CcSEcCtD
Dobutamine—Thrombocytopenia—Etoposide—hematologic cancer	0.00043	0.00107	CcSEcCtD
Dobutamine—Tachycardia—Etoposide—hematologic cancer	0.000429	0.00107	CcSEcCtD
Dobutamine—Dyspnoea—Cisplatin—hematologic cancer	0.000427	0.00106	CcSEcCtD
Dobutamine—Nausea—Lenalidomide—hematologic cancer	0.000423	0.00105	CcSEcCtD
Dobutamine—Tachycardia—Prednisolone—hematologic cancer	0.000423	0.00105	CcSEcCtD
Dobutamine—Hypokalaemia—Doxorubicin—hematologic cancer	0.000422	0.00105	CcSEcCtD
Dobutamine—Angina pectoris—Epirubicin—hematologic cancer	0.000422	0.00105	CcSEcCtD
Dobutamine—Pruritus—Thalidomide—hematologic cancer	0.000418	0.00104	CcSEcCtD
Dobutamine—Nausea—Hydroxyurea—hematologic cancer	0.000417	0.00104	CcSEcCtD
Dobutamine—Headache—Bortezomib—hematologic cancer	0.000411	0.00102	CcSEcCtD
Dobutamine—Hypotension—Etoposide—hematologic cancer	0.00041	0.00102	CcSEcCtD
Dobutamine—Headache—Vinorelbine—hematologic cancer	0.000401	0.000997	CcSEcCtD
Dobutamine—Pruritus—Alitretinoin—hematologic cancer	0.000398	0.00099	CcSEcCtD
Dobutamine—Pruritus—Ifosfamide—hematologic cancer	0.000393	0.000978	CcSEcCtD
Dobutamine—Dyspnoea—Etoposide—hematologic cancer	0.000392	0.000974	CcSEcCtD
Dobutamine—Angina pectoris—Doxorubicin—hematologic cancer	0.00039	0.00097	CcSEcCtD
Dobutamine—Nausea—Bortezomib—hematologic cancer	0.000389	0.000968	CcSEcCtD
Dobutamine—Tachycardia—Triamcinolone—hematologic cancer	0.000389	0.000967	CcSEcCtD
Dobutamine—Nausea—Bleomycin—hematologic cancer	0.000386	0.000961	CcSEcCtD
Dobutamine—Headache—Thiotepa—hematologic cancer	0.000383	0.000952	CcSEcCtD
Dobutamine—Nausea—Vinorelbine—hematologic cancer	0.00038	0.000946	CcSEcCtD
Dobutamine—Headache—Thalidomide—hematologic cancer	0.00037	0.000921	CcSEcCtD
Dobutamine—Pruritus—Gemcitabine—hematologic cancer	0.000364	0.000905	CcSEcCtD
Dobutamine—Nausea—Thiotepa—hematologic cancer	0.000363	0.000903	CcSEcCtD
Dobutamine—Headache—Carmustine—hematologic cancer	0.000356	0.000885	CcSEcCtD
Dobutamine—Dyspnoea—Triamcinolone—hematologic cancer	0.000355	0.000883	CcSEcCtD
Dobutamine—Thrombocytopenia—Dexamethasone—hematologic cancer	0.000354	0.00088	CcSEcCtD
Dobutamine—Thrombocytopenia—Betamethasone—hematologic cancer	0.000354	0.00088	CcSEcCtD
Dobutamine—Tachycardia—Dexamethasone—hematologic cancer	0.000353	0.000877	CcSEcCtD
Dobutamine—Tachycardia—Betamethasone—hematologic cancer	0.000353	0.000877	CcSEcCtD
Dobutamine—Headache—Alitretinoin—hematologic cancer	0.000352	0.000876	CcSEcCtD
Dobutamine—Nausea—Thalidomide—hematologic cancer	0.000351	0.000873	CcSEcCtD
Dobutamine—Headache—Vincristine—hematologic cancer	0.00034	0.000844	CcSEcCtD
Dobutamine—Hypotension—Betamethasone—hematologic cancer	0.000338	0.00084	CcSEcCtD
Dobutamine—Hypotension—Dexamethasone—hematologic cancer	0.000338	0.00084	CcSEcCtD
Dobutamine—Nausea—Carmustine—hematologic cancer	0.000337	0.000839	CcSEcCtD
Dobutamine—Nausea—Alitretinoin—hematologic cancer	0.000334	0.000831	CcSEcCtD
Dobutamine—Headache—Mitoxantrone—hematologic cancer	0.000331	0.000822	CcSEcCtD
Dobutamine—Headache—Irinotecan—hematologic cancer	0.000331	0.000822	CcSEcCtD
Dobutamine—Nausea—Ifosfamide—hematologic cancer	0.00033	0.000821	CcSEcCtD
Dobutamine—Headache—Gemcitabine—hematologic cancer	0.000322	0.000801	CcSEcCtD
Dobutamine—Nausea—Vincristine—hematologic cancer	0.000322	0.000801	CcSEcCtD
Dobutamine—Nausea—Irinotecan—hematologic cancer	0.000314	0.00078	CcSEcCtD
Dobutamine—Nausea—Mitoxantrone—hematologic cancer	0.000314	0.00078	CcSEcCtD
Dobutamine—Pruritus—Etoposide—hematologic cancer	0.000311	0.000773	CcSEcCtD
Dobutamine—Tachycardia—Prednisone—hematologic cancer	0.000307	0.000764	CcSEcCtD
Dobutamine—Nausea—Gemcitabine—hematologic cancer	0.000306	0.00076	CcSEcCtD
Dobutamine—Nausea—Cisplatin—hematologic cancer	0.000285	0.000708	CcSEcCtD
Dobutamine—Pruritus—Triamcinolone—hematologic cancer	0.000282	0.000701	CcSEcCtD
Dobutamine—Headache—Etoposide—hematologic cancer	0.000275	0.000684	CcSEcCtD
Dobutamine—Chest pain—Methotrexate—hematologic cancer	0.000274	0.000682	CcSEcCtD
Dobutamine—Headache—Prednisolone—hematologic cancer	0.000271	0.000675	CcSEcCtD
Dobutamine—Palpitations—Epirubicin—hematologic cancer	0.000267	0.000663	CcSEcCtD
Dobutamine—Nausea—Etoposide—hematologic cancer	0.000261	0.000649	CcSEcCtD
Dobutamine—Thrombocytopenia—Methotrexate—hematologic cancer	0.000258	0.00064	CcSEcCtD
Dobutamine—Nausea—Prednisolone—hematologic cancer	0.000257	0.00064	CcSEcCtD
Dobutamine—Chest pain—Epirubicin—hematologic cancer	0.000257	0.000639	CcSEcCtD
Dobutamine—Pruritus—Betamethasone—hematologic cancer	0.000256	0.000636	CcSEcCtD
Dobutamine—Pruritus—Dexamethasone—hematologic cancer	0.000256	0.000636	CcSEcCtD
Dobutamine—Headache—Triamcinolone—hematologic cancer	0.00025	0.00062	CcSEcCtD
Dobutamine—Palpitations—Doxorubicin—hematologic cancer	0.000247	0.000613	CcSEcCtD
Dobutamine—Hypotension—Methotrexate—hematologic cancer	0.000246	0.000611	CcSEcCtD
Dobutamine—Thrombocytopenia—Epirubicin—hematologic cancer	0.000241	0.000599	CcSEcCtD
Dobutamine—Tachycardia—Epirubicin—hematologic cancer	0.00024	0.000597	CcSEcCtD
Dobutamine—Chest pain—Doxorubicin—hematologic cancer	0.000238	0.000591	CcSEcCtD
Dobutamine—Nausea—Triamcinolone—hematologic cancer	0.000237	0.000588	CcSEcCtD
Dobutamine—Dyspnoea—Methotrexate—hematologic cancer	0.000235	0.000583	CcSEcCtD
Dobutamine—Hypotension—Epirubicin—hematologic cancer	0.00023	0.000572	CcSEcCtD
Dobutamine—Headache—Betamethasone—hematologic cancer	0.000226	0.000563	CcSEcCtD
Dobutamine—Headache—Dexamethasone—hematologic cancer	0.000226	0.000563	CcSEcCtD
Dobutamine—Thrombocytopenia—Doxorubicin—hematologic cancer	0.000223	0.000555	CcSEcCtD
Dobutamine—Pruritus—Prednisone—hematologic cancer	0.000223	0.000554	CcSEcCtD
Dobutamine—Tachycardia—Doxorubicin—hematologic cancer	0.000222	0.000553	CcSEcCtD
Dobutamine—Dyspnoea—Epirubicin—hematologic cancer	0.000219	0.000546	CcSEcCtD
Dobutamine—Nausea—Dexamethasone—hematologic cancer	0.000215	0.000534	CcSEcCtD
Dobutamine—Nausea—Betamethasone—hematologic cancer	0.000215	0.000534	CcSEcCtD
Dobutamine—Hypotension—Doxorubicin—hematologic cancer	0.000213	0.000529	CcSEcCtD
Dobutamine—Dyspnoea—Doxorubicin—hematologic cancer	0.000203	0.000505	CcSEcCtD
Dobutamine—Headache—Prednisone—hematologic cancer	0.000197	0.00049	CcSEcCtD
Dobutamine—Nausea—Prednisone—hematologic cancer	0.000187	0.000465	CcSEcCtD
Dobutamine—Pruritus—Methotrexate—hematologic cancer	0.000186	0.000463	CcSEcCtD
Dobutamine—Pruritus—Epirubicin—hematologic cancer	0.000174	0.000433	CcSEcCtD
Dobutamine—Headache—Methotrexate—hematologic cancer	0.000165	0.00041	CcSEcCtD
Dobutamine—Pruritus—Doxorubicin—hematologic cancer	0.000161	0.000401	CcSEcCtD
Dobutamine—Nausea—Methotrexate—hematologic cancer	0.000156	0.000389	CcSEcCtD
Dobutamine—Headache—Epirubicin—hematologic cancer	0.000154	0.000383	CcSEcCtD
Dobutamine—Nausea—Epirubicin—hematologic cancer	0.000146	0.000364	CcSEcCtD
Dobutamine—Headache—Doxorubicin—hematologic cancer	0.000143	0.000355	CcSEcCtD
Dobutamine—Nausea—Doxorubicin—hematologic cancer	0.000135	0.000336	CcSEcCtD
Dobutamine—ADRB1—Signaling Pathways—GZMB—hematologic cancer	3.02e-05	0.000213	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PRKCG—hematologic cancer	2.98e-05	0.00021	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—JAK1—hematologic cancer	2.98e-05	0.00021	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SH2B3—hematologic cancer	2.97e-05	0.00021	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SMARCA4—hematologic cancer	2.97e-05	0.00021	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GZMB—hematologic cancer	2.95e-05	0.000208	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CTNNA1—hematologic cancer	2.94e-05	0.000208	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CREBBP—hematologic cancer	2.94e-05	0.000207	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EIF4EBP1—hematologic cancer	2.93e-05	0.000207	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CCL3—hematologic cancer	2.93e-05	0.000207	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HSPB1—hematologic cancer	2.93e-05	0.000207	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CB—hematologic cancer	2.9e-05	0.000205	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTHLH—hematologic cancer	2.9e-05	0.000204	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SDC1—hematologic cancer	2.9e-05	0.000204	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CTNNA1—hematologic cancer	2.88e-05	0.000203	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EIF4EBP1—hematologic cancer	2.86e-05	0.000202	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CCL3—hematologic cancer	2.86e-05	0.000202	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HSPB1—hematologic cancer	2.86e-05	0.000202	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL2RA—hematologic cancer	2.85e-05	0.000201	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTHLH—hematologic cancer	2.83e-05	0.0002	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SDC1—hematologic cancer	2.83e-05	0.0002	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTGER4—hematologic cancer	2.82e-05	0.000199	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—LCK—hematologic cancer	2.8e-05	0.000198	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CD—hematologic cancer	2.79e-05	0.000197	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL2RA—hematologic cancer	2.78e-05	0.000197	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTGER4—hematologic cancer	2.76e-05	0.000195	CbGpPWpGaD
Dobutamine—COMT—Metabolism—ALB—hematologic cancer	2.75e-05	0.000194	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—H3F3A—hematologic cancer	2.75e-05	0.000194	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—LCK—hematologic cancer	2.74e-05	0.000194	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—H3F3A—hematologic cancer	2.69e-05	0.00019	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PRKCZ—hematologic cancer	2.67e-05	0.000189	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PIK3CA—hematologic cancer	2.67e-05	0.000189	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3R1—hematologic cancer	2.63e-05	0.000186	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PRKCZ—hematologic cancer	2.61e-05	0.000185	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CG—hematologic cancer	2.61e-05	0.000184	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PARP1—hematologic cancer	2.58e-05	0.000182	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CG—hematologic cancer	2.55e-05	0.00018	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FBXW7—hematologic cancer	2.54e-05	0.000179	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PARP1—hematologic cancer	2.52e-05	0.000178	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTEN—hematologic cancer	2.5e-05	0.000177	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PIK3CA—hematologic cancer	2.49e-05	0.000176	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HDAC2—hematologic cancer	2.49e-05	0.000176	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CXCR4—hematologic cancer	2.49e-05	0.000176	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FBXW7—hematologic cancer	2.48e-05	0.000175	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CXCR4—hematologic cancer	2.44e-05	0.000172	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HDAC2—hematologic cancer	2.44e-05	0.000172	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CB—hematologic cancer	2.43e-05	0.000171	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CBL—hematologic cancer	2.43e-05	0.000171	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL3—hematologic cancer	2.4e-05	0.000169	CbGpPWpGaD
Dobutamine—CA2—Metabolism—EP300—hematologic cancer	2.39e-05	0.000169	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CBL—hematologic cancer	2.37e-05	0.000168	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CG—hematologic cancer	2.37e-05	0.000167	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTPN1—hematologic cancer	2.36e-05	0.000167	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL3—hematologic cancer	2.35e-05	0.000166	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PTPN11—hematologic cancer	2.33e-05	0.000164	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—RASGRP1—hematologic cancer	2.32e-05	0.000164	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CG—hematologic cancer	2.32e-05	0.000164	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HSP90AA1—hematologic cancer	2.31e-05	0.000163	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SYK—hematologic cancer	2.31e-05	0.000163	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTPN1—hematologic cancer	2.31e-05	0.000163	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.3e-05	0.000162	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PTPN11—hematologic cancer	2.28e-05	0.000161	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—RASGRP1—hematologic cancer	2.27e-05	0.00016	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HSP90AA1—hematologic cancer	2.26e-05	0.00016	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SYK—hematologic cancer	2.26e-05	0.00016	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—CREB1—hematologic cancer	2.26e-05	0.000159	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CD—hematologic cancer	2.25e-05	0.000159	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—STAT1—hematologic cancer	2.23e-05	0.000158	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—CCL2—hematologic cancer	2.21e-05	0.000156	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	2.21e-05	0.000156	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL6R—hematologic cancer	2.2e-05	0.000155	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—STAT1—hematologic cancer	2.18e-05	0.000154	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—AKT1—hematologic cancer	2.18e-05	0.000154	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.17e-05	0.000153	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	2.16e-05	0.000153	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	2.15e-05	0.000152	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	2.12e-05	0.00015	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	2.11e-05	0.000149	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	2.1e-05	0.000148	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTEN—hematologic cancer	2.1e-05	0.000148	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GRB2—hematologic cancer	2.09e-05	0.000147	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	2.08e-05	0.000147	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	2.08e-05	0.000147	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	2.06e-05	0.000145	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KITLG—hematologic cancer	2.05e-05	0.000145	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	2.05e-05	0.000145	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GRB2—hematologic cancer	2.04e-05	0.000144	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	2.04e-05	0.000144	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—AKT1—hematologic cancer	2.04e-05	0.000144	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	2.04e-05	0.000144	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KITLG—hematologic cancer	2.01e-05	0.000142	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	2.01e-05	0.000142	CbGpPWpGaD
Dobutamine—COMT—Metabolism—EP300—hematologic cancer	2e-05	0.000141	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	2e-05	0.000141	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	1.99e-05	0.00014	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	1.97e-05	0.000139	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	1.96e-05	0.000139	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	1.96e-05	0.000138	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	1.95e-05	0.000137	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	1.93e-05	0.000136	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CD86—hematologic cancer	1.92e-05	0.000136	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	1.91e-05	0.000135	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HES1—hematologic cancer	1.9e-05	0.000134	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	1.89e-05	0.000133	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CD86—hematologic cancer	1.88e-05	0.000133	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	1.87e-05	0.000132	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CSF2—hematologic cancer	1.87e-05	0.000132	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGF1—hematologic cancer	1.87e-05	0.000132	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HES1—hematologic cancer	1.86e-05	0.000131	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	1.85e-05	0.00013	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	1.84e-05	0.00013	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	1.84e-05	0.00013	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	1.84e-05	0.00013	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGF1—hematologic cancer	1.83e-05	0.000129	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CSF2—hematologic cancer	1.83e-05	0.000129	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	1.82e-05	0.000128	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	1.81e-05	0.000128	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—JAK1—hematologic cancer	1.8e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	1.8e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	1.8e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	1.8e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	1.8e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	1.78e-05	0.000125	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	1.77e-05	0.000125	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CA—hematologic cancer	1.77e-05	0.000125	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—JAK1—hematologic cancer	1.76e-05	0.000124	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	1.76e-05	0.000124	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	1.68e-05	0.000119	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL2—hematologic cancer	1.67e-05	0.000118	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TERT—hematologic cancer	1.66e-05	0.000117	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	1.65e-05	0.000116	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL2—hematologic cancer	1.63e-05	0.000115	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TERT—hematologic cancer	1.63e-05	0.000115	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	1.62e-05	0.000115	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	1.59e-05	0.000112	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TSC2—hematologic cancer	1.59e-05	0.000112	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TSC2—hematologic cancer	1.55e-05	0.00011	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	1.53e-05	0.000108	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	1.51e-05	0.000107	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	1.49e-05	0.000105	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ESR1—hematologic cancer	1.48e-05	0.000105	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CA—hematologic cancer	1.48e-05	0.000105	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	1.48e-05	0.000104	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FN1—hematologic cancer	1.46e-05	0.000103	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ESR1—hematologic cancer	1.45e-05	0.000102	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—BAD—hematologic cancer	1.45e-05	0.000102	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	1.45e-05	0.000102	CbGpPWpGaD
Dobutamine—CA2—Metabolism—AKT1—hematologic cancer	1.44e-05	0.000102	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	1.43e-05	0.000101	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FN1—hematologic cancer	1.43e-05	0.000101	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	1.42e-05	9.99e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—BAD—hematologic cancer	1.42e-05	9.99e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CD80—hematologic cancer	1.4e-05	9.91e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	1.4e-05	9.89e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	1.4e-05	9.89e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KIT—hematologic cancer	1.4e-05	9.89e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	1.4e-05	9.89e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	1.38e-05	9.72e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CD80—hematologic cancer	1.37e-05	9.69e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	1.37e-05	9.67e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KIT—hematologic cancer	1.37e-05	9.67e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	1.37e-05	9.67e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	1.35e-05	9.5e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	1.34e-05	9.47e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CREB1—hematologic cancer	1.33e-05	9.41e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—BRAF—hematologic cancer	1.32e-05	9.3e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	1.31e-05	9.27e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CCL2—hematologic cancer	1.3e-05	9.21e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CREB1—hematologic cancer	1.3e-05	9.21e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL6R—hematologic cancer	1.3e-05	9.18e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	1.3e-05	9.17e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—BRAF—hematologic cancer	1.29e-05	9.09e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CCL2—hematologic cancer	1.28e-05	9.01e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL6R—hematologic cancer	1.27e-05	8.98e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	1.27e-05	8.97e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	1.24e-05	8.75e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	1.23e-05	8.69e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.22e-05	8.61e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	1.21e-05	8.56e-05	CbGpPWpGaD
Dobutamine—COMT—Metabolism—AKT1—hematologic cancer	1.21e-05	8.54e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	1.21e-05	8.51e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	1.2e-05	8.5e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.19e-05	8.42e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	1.18e-05	8.33e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGF2—hematologic cancer	1.18e-05	8.32e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	1.16e-05	8.21e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGF2—hematologic cancer	1.15e-05	8.14e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	1.14e-05	8.03e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—JAK2—hematologic cancer	1.13e-05	7.98e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	1.11e-05	7.82e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—JAK2—hematologic cancer	1.11e-05	7.81e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MDM2—hematologic cancer	1.1e-05	7.79e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	1.08e-05	7.65e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MDM2—hematologic cancer	1.08e-05	7.62e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MTOR—hematologic cancer	1.07e-05	7.58e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	1.07e-05	7.58e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MTOR—hematologic cancer	1.05e-05	7.41e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	1.05e-05	7.41e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	1.02e-05	7.24e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	1e-05	7.08e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	9.97e-06	7.03e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CASP3—hematologic cancer	9.87e-06	6.97e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL2—hematologic cancer	9.86e-06	6.96e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	9.86e-06	6.96e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL6—hematologic cancer	9.81e-06	6.92e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	9.75e-06	6.88e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CASP3—hematologic cancer	9.66e-06	6.82e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL2—hematologic cancer	9.64e-06	6.81e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CCND1—hematologic cancer	9.61e-06	6.78e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL6—hematologic cancer	9.6e-06	6.77e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—JUN—hematologic cancer	9.59e-06	6.77e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CCND1—hematologic cancer	9.4e-06	6.64e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—JUN—hematologic cancer	9.38e-06	6.62e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	9.3e-06	6.56e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTEN—hematologic cancer	9.28e-06	6.55e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	9.09e-06	6.42e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	9.07e-06	6.41e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTEN—hematologic cancer	9.07e-06	6.41e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	9.05e-06	6.39e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	8.88e-06	6.27e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	8.85e-06	6.25e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EP300—hematologic cancer	8.85e-06	6.24e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EP300—hematologic cancer	8.65e-06	6.11e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SRC—hematologic cancer	8.6e-06	6.07e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SRC—hematologic cancer	8.42e-06	5.94e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	8.38e-06	5.91e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—STAT3—hematologic cancer	8.3e-06	5.86e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NRAS—hematologic cancer	8.28e-06	5.84e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	8.2e-06	5.79e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—STAT3—hematologic cancer	8.12e-06	5.73e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NRAS—hematologic cancer	8.1e-06	5.71e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	7.93e-06	5.6e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	7.75e-06	5.47e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MYC—hematologic cancer	7.71e-06	5.44e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	7.69e-06	5.43e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MYC—hematologic cancer	7.54e-06	5.32e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	7.52e-06	5.31e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KRAS—hematologic cancer	7.12e-06	5.03e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KRAS—hematologic cancer	6.97e-06	4.92e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	6.54e-06	4.62e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	6.4e-06	4.52e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TP53—hematologic cancer	6.33e-06	4.47e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TP53—hematologic cancer	6.19e-06	4.37e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HRAS—hematologic cancer	6.05e-06	4.27e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HRAS—hematologic cancer	5.92e-06	4.18e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL6—hematologic cancer	5.79e-06	4.09e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL6—hematologic cancer	5.67e-06	4e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—AKT1—hematologic cancer	5.35e-06	3.77e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—AKT1—hematologic cancer	5.23e-06	3.69e-05	CbGpPWpGaD
